Research and Markets: New 2013 Report Exploring the Role of Nanotechnology in the Energy Industry

Posted on by

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/b6jwc5/role_of) has announced the addition of the "Role of Nanotechnology in the Energy Industry" report to their offering.

Nanotechnology is the study of manipulating matter on an atomic and molecular scale.

Nanotechnology is very diverse, ranging from extensions of conventional device physics to completely new approaches based upon molecular self-assembly, from developing new materials with dimensions on the nanoscale to investigating whether we can directly control matter on the atomic scale.

Nano-engineered materials offer extraordinary new capabilities for the improvement of energy generation and efficiency. The use of high surface-to-area ratio carbon nanotubes in battery electrodes generates an increase in electricity output over traditional electrodes.

Some of the segments of the energy industry where nanotech is being used to include:

- Oil and gas extraction

- Solar power

- Fuel cells

- Wind power

More here:

Research and Markets: New 2013 Report Exploring the Role of Nanotechnology in the Energy Industry

World Nanotechnology Market Potential Explored by RNCOS in New Topical Study Now Available at MarketPublishers.com

Posted on by

LONDON--(BUSINESS WIRE)--

The global nanotechnology industry has been advancing at a robust rate in the recent past and it is likely to register a healthy CAGR of around 19% during 2013-2017. Major factors booming this growth include the growing penetration of nanotechnology into various industrial sectors; market trends such as the emergence of nanomaterials with higher strength, nanotechnology-based thin film solar cells with high efficiency, rapid popularity of nanofibres and nanomedicine, among others.

New market research study Nanotechnology Market Outlook 2017 elaborated by RNCOS E-Services Private Limited (RNCOS) is designed to give a refined understanding of the prospects of the global nanotechnology industry.

The research provides an in-depth review and forecast up to 2017 of the global nanotechnology market, segmented by application (electronics, energy, cosmetics, biomedical and defense), component (nanomaterials, nanotools and nanodevices) and by individual country the US, Brazil, Germany, France, the UK, Ireland, Russia, Japan, South Korea, Taiwan, China, India and Australia. The report provides key market trends and developments, growth drivers and future directions for each nation covered. Further, the research covers the nanotechnology patent analyses, including the number of patent publications and global top assignees of nanotechnology patent literature. It also covers the global RnD funding for the nanotechnology industry, including break-ups for corporate, public and venture capital funding along with their forecasts. The report even covers country-level analysis of R&D funding to provide in-depth understanding about investment related to nanotechnology.

Companies discussed include: Altair Nanotechnologies Inc., Nanophase Technologies Corporation, Nanosys, Inc., Unidym, Inc., Ablynx, NanoScale Corporation, Zyvex Corporation, Acusphere, Inc., SouthWest NanoTechnologies, Inc., and Applied Nanotech Holdings, Inc.

Report Details:

Title: Nanotechnology Market Outlook 2017

Published: May, 2013

Pages:210

Price: US$ 1,500.00

Visit link:

World Nanotechnology Market Potential Explored by RNCOS in New Topical Study Now Available at MarketPublishers.com

John Stossel – Free Market or Government Medicine: What Will Be The New Way? 4/25/13 – Video

Posted on by


John Stossel - Free Market or Government Medicine: What Will Be The New Way? 4/25/13
April 25th This video may contain copyrighted material. Such material is made available for educational purposes only. This constitutes a #39;fair use #39; of any s...

By: selfownership1

See the original post:

John Stossel - Free Market or Government Medicine: What Will Be The New Way? 4/25/13 - Video

Cytomedix to Present at the World Stem Cells & Regenerative Medicine Congress 2013

Posted on by

GAITHERSBURG, MD--(Marketwired - May 17, 2013) - Cytomedix, Inc. (OTCQX: CMXI), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies, announced today that Edward Field, the Company's Chief Operating Officer, has been invited to make a presentation on Partnering & Collaboration at the World Stem Cells & Regenerative Medicine Congress 2013, which will be held May 21-23, 2013 in London, United Kingdom.

Presentation Details

Time: Tuesday, May 21, 2013 @ 11:55am BST (6:55 am EST)

Track Title: Commercialisation through Collaboration: What Does Partnering In This Industry Actually Look Like?

Location: Victoria Park Plaza Hotel, London, UK

During the presentation, Mr. Field will highlight Cytomedix's two collaborations that are advancing clinical stage therapies.The first is a collaboration with the National Institute of Health (NIH) and the Cardiovascular Cell Therapy Research Network (CCTRN) for conduct of the PACE study, an 80 patient, double-blind, placebo-controlled clinical trial designed to look at the safety and efficacy of ALD-301 in peripheral artery disease patients diagnosed with intermittent claudication.This is the first ever randomized clinical trial to look at the benefits of autologous stem cell therapy in this indication.The second collaboration is with Duke University Medical Center, which is conducting a Phase 1 clinical study with ALD-451 in patients that have been treated for glioblastomas, which is the most aggressive form of brain cancer.This open-label study is designed to enroll up to 12 patients and is intended to demonstrate the safety and feasibility of ALD-451 when administered intravenously in patients with grade IV malignant glioma following surgery, radiation therapy and treatment with temozolomide.

About the World Stem Cells Regenerative Medicine Congress 2013The World Stem Cells & Regenerative Medicine Congress 2013 is Europe's largest and most senior conference for the stem cell research and regenerative medicine community.It is now in its 8th year. Topics covered will include streamlining clinical development, commercialising a stem cell-based therapy and exploiting alternative sources of funding. For more information please visit: http://www.terrapinn.com/2013/stemcells/index.stm.

About Cytomedix, Inc. Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. Our commercial products include the AutoloGel System, cleared by the FDA for wound care and the Angel Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDH") technology to isolate a unique, biologically active population of a patient's own stem cells. A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit http://www.cytomedix.com.

Safe Harbor Statement - Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's ability to successfully execute its Angel and AutoloGel sales strategies, to achieve AutoloGel expected reimbursement rates in 2013, to meet its stroke trial enrollment rates, the Company's ability to successfully integrate the Aldagen acquisition, the Company's ability to expand patient populations as contemplated, its ability to provide Medicare patients with access as expected, the Company's expectations of favorable future dialogue with potential strategic partners, and its ability to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes," "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2012, as amended to date, and other subsequent filings. These filings are available at http://www.sec.gov.

Follow this link:

Cytomedix to Present at the World Stem Cells & Regenerative Medicine Congress 2013

MMRGlobal Adds Concierge Medicine Specialist Jeremy Fine, M.D. and Pediatrician and New York Times Best-Selling Author …

Posted on by

LOS ANGELES, CA--(Marketwired - May 17, 2013) - MMRGlobal, Inc. (OTCQB: MMRF) ("MMR"), a leading provider of Personal Health Records (PHRs) MyEsafeDepositBox storage solutions and MMRPro document management and imaging systems for healthcare professionals, today announced the addition of two new members to its Medical Board of Advisors.Dr. Cara Natterson, M.D., a Board-Certified Pediatrician, consultant and The New York Times best-selling author on child health and parenting, will assist the Company with its plans to educate parents on the importance of having a Personal Health Record for their children as well as the best ways to offer PHR products and services through pediatricians.Dr. Jeremy Fine, M.D. is a Concierge Medicine Specialist and Board-Certified in Internal Medicine. Based on his personal experience, Dr. Fine will assist the Company educating Concierge Medicine professionals on the value of ensuring that patients maintain an up-to-date PHR. The announcement was made following MMRGlobal CEO Bob Lorsch's appearance on Fox News Radio in a 30-minute interview on "The Vipp Jaswal Report."During the interview, which is available at https://www.facebook.com/#!/MMRGlobal?fref=ts, Lorsch discussed MMR's business and how efforts in Washington to encourage steering a portion of $27 billion in health IT stimulus to emerging growth companies like MMR brought him and his wife Kira to spearhead a humanitarian effort regarding the release of Dr. Shakil Afridi.

Dr. Natterson has written five books, including "Worry Proof," winner of the The Wall Street Journal's Best Health Book of the Year Award, and authored the American Girl book, "The Care & Keeping of You 2."She also updated American Girl's original "The Care & Keeping of You," which has sold over three million copies. Dr. Fine has served on the Executive Committee, Bioethics Committee and the Medical Informatics Committee at Cedars-Sinai Medical Center. He is a former Clinical Instructor of Medicine at both the UCLA and USC Schools of Medicine and was chosen by Los Angeles Magazine as one of the Best Doctors in Los Angeles.

According to Lorsch, "Dr. Natterson and Dr. Fine will make a great addition to the Company's Medical Board of Advisors, helping us educate two specialty markets on the value of PHRs. Dr. Natterson's role is to strategically introduce MyMedicalRecords to the pediatric market in an effort to make both pediatricians and parents aware of the importance of having a PHR for children at a very young age. Dr. Jeremy Fine truly exemplifies what Concierge Medicine is all about and being there for his patients whenever and wherever they need him."

Over the past several years, Dr. Fine routinely deployed MyMedicalRecords accounts to his Concierge Medicine patients as part of his Concierge Medicine protocol."As a result, Dr. Fine knows first-hand how valuable it can be in an emergency at 2 a.m. to have the ability to log in to MyMedicalRecords and access a patient's critical information regardless of where he or his patients are in the world. Consumer awareness of the importance of having a PHR is critical to the Company's business plan and there are no better professionals than Drs. Natterson and Fine to carry our message to physician colleagues, patients and parents," Lorsch added.

Working with qualified healthcare professionals, including the Company's medical advisers, MMR continues to focus on the deployment of its Personal Health Record products and services and the licensing of its patented technologies. MMRGlobal generates revenue from the sale of Personal Health Records to employers for employee benefits, direct to consumers, and patients. Through the MMR Stimulus Program, physicians and hospitals that offer MyMedicalRecords PHRs to patients can receive hundreds of thousands of dollars back from MMR as a reimbursement for the costs of maintaining medical records.

Following are brief biographies of the two new members of the Medical Board Advisors:

Dr. Jeremy Fine

Dr. Fine completed his medical training in internal medicine at Cedars-Sinai Medical Center in 2004 and was then selected to be Chief Resident. He has served on the Executive Committee, Bioethics Committee and the Medical Informatics Committee at Cedars-Sinai Medical Center. He is also a former Clinical Instructor of Medicine at both the UCLA and USC Schools of Medicine. He was chosen by Los Angeles Magazine as one of the Best Doctors in Los Angeles and has also been selected as one of California's Favorite Physicians. In 2010, he was voted Most Compassionate Doctor.

Dr. Cara Natterson

Dr. Natterson is a graduate of Harvard College and Johns Hopkins School of Medicine, trained in pediatrics at the University of California at San Francisco, and is a Board-Certified pediatrician and a Fellow of the American Academy of Pediatrics. A former partner at Tenth Street Pediatrics in Santa Monica, California, she now runs Worry Proof Consulting, the first of its kind pediatric practice that offers parents open-ended time to review everything from medical questions and biology basics to child development and parenting issues. Dr. Natterson appears on television, in print, and on the web, and is a New York Times bestselling author, having written several books on parenting and child health. Her most recent titles were published in February 2013: "The Care and Keeping of You 1: The Body Book for Younger Girls" and "The Care and Keeping of You 2: The Body Book for Older Girls." Dr. Natterson's consulting includes Fortune 500 companies seeking expert advice on child health, wellness and safety issues.

More here:

MMRGlobal Adds Concierge Medicine Specialist Jeremy Fine, M.D. and Pediatrician and New York Times Best-Selling Author ...

GfK to Share Insights on Personalized Medicine, Complex Treatment Regimens At PBIRG Annual Meeting

Posted on by

NEW YORK--(BUSINESS WIRE)--

GfK will deliver a major presentation about patient perspectives on personalized medicine at thePharmaceutical Business and Intelligence Research Group (PBIRG) Annual General Meeting, taking place May 19 to 22 in Naples, Florida.

Gavin Erickson, Principal Consultant at GfK Bridgehead, will lead the session, titled Shifting the Paradigm: Patient Knowledge, Attitudes, and Behaviors Hold the Key for Personalized Medicine. Erickson will review key aspects of the personalized medicine phenomenon, such as:

With hundreds of new biologic agents in development today, the coming tide of targeted therapies and companion diagnostics creates both opportunities and challenges for the industry, said Erickson. Patient-centric information can help manufacturers, clinicians, policy makers and payers understand the implications of personalized medicine, as we move away from one size fits all sales and marketing strategies.

Erickson has over 17 years of experience in the healthcare field, with deep knowledge of coding, coverage and payment for both Medicare and commercial health insurance. His fields of expertise include global health economics and reimbursement, hospital contracting and data analytics in the diagnostic, medical device and pharmaceutical, and commercial health plan space.

In addition, GfKs Sara Doran, Senior Research Director on GfKs Health team, will present a poster on GfKs Novel Approach to Navigating the Web of Complex Treatment Regimens. The poster focuses on a new specialty medicine market entrant, offering a clear understanding of fit versus adoption, how to illustrate complex regimen changes over time, and what drives adoption of one regimen over another.

Dorans 11 years of research experience include both US and global custom projects, with deep quantitative expertise. She has managed strategic and tactical research studies with physicians, patients and caregivers and has worked on an array of research methodologies.

GfK is sponsoring the PBIRG Opening Reception on May 19 at 7:00PM PBIRG conference attendees can visit the companys booths (# 27/28); in addition, GfK Bridgehead has authored a feature article on personalized medicine in the Spring 2013 PBIRG Perspective.

About GfK

GfK is one of the worlds largest research companies, with more than 12,000 experts working to discover new insights into the way people live, think and shop, in over 100 markets, every day. GfK is constantly innovating and using the latest technologies and the smartest methodologies to give its clients the clearest understanding of the most important people in the world: their customers. In 2012,GfKs sales amounted to EUR 1.51 billion.

Read more:

GfK to Share Insights on Personalized Medicine, Complex Treatment Regimens At PBIRG Annual Meeting